These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16055015)

  • 21. Invasive properties of multidrug resistant human melanoma cells.
    Molinari A; Stringaro A; Gentile M; Colone M; Toccacieli L; Arancia G
    Ital J Anat Embryol; 2005; 110(2 Suppl 1):135-41. PubMed ID: 16101031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted agents: the rules of combination.
    Kwak EL; Clark JW; Chabner B
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advances in studies on inhibitor of apoptosis proteins and cancer therapy].
    Wang XH; Fu LW
    Yao Xue Xue Bao; 2006 Feb; 41(2):103-7. PubMed ID: 16671537
    [No Abstract]   [Full Text] [Related]  

  • 25. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
    Wang SJ; Peyrollier K; Bourguignon LY
    Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells.
    Xu W; Neckers L
    Clin Cancer Res; 2007 Mar; 13(6):1625-9. PubMed ID: 17363512
    [No Abstract]   [Full Text] [Related]  

  • 27. Molecular and physiologic mechanisms of drug resistance in cancer: an overview.
    Kerbel RS
    Cancer Metastasis Rev; 2001; 20(1-2):1-2. PubMed ID: 11831636
    [No Abstract]   [Full Text] [Related]  

  • 28. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The resurgence of platinum-based cancer chemotherapy.
    Kelland L
    Nat Rev Cancer; 2007 Aug; 7(8):573-84. PubMed ID: 17625587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dodging a dogma: is treating beyond progression beneficial?
    Naing A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 May; 71(5):1385-6. PubMed ID: 23443308
    [No Abstract]   [Full Text] [Related]  

  • 31. Effective strategies for tumors affecting chemopreventive metabolism.
    Buters JT
    Clin Cancer Res; 2006 Dec; 12(24):7203-4. PubMed ID: 17189389
    [No Abstract]   [Full Text] [Related]  

  • 32. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug resistance in cancer: a perspective.
    Goldie JH
    Cancer Metastasis Rev; 2001; 20(1-2):63-8. PubMed ID: 11831649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakthrough in cancer treatment.
    van der Linde I
    S Afr Med J; 1998 Jul; 88(7):813. PubMed ID: 9698707
    [No Abstract]   [Full Text] [Related]  

  • 35. Imaging of tumor characteristics for tailored therapy.
    de Vries E
    Curr Pharm Des; 2008; 14(28):2912-3. PubMed ID: 18991709
    [No Abstract]   [Full Text] [Related]  

  • 36. Bioreductive agents, hypoxic cells and therapy.
    Connors TA
    Eur J Cancer; 1996 Oct; 32A(11):1833-4. PubMed ID: 8943663
    [No Abstract]   [Full Text] [Related]  

  • 37. Remaining hurdles to effective cancer therapy.
    Schaffhausen J
    Trends Pharmacol Sci; 2015 Jun; 36(6):v. PubMed ID: 25959521
    [No Abstract]   [Full Text] [Related]  

  • 38. The Molecular Oncology of Drug Resistance: Targets, Drugs and Chemical Biology.
    Beretta GL
    Curr Med Chem; 2019; 26(33):6018-6019. PubMed ID: 31518215
    [No Abstract]   [Full Text] [Related]  

  • 39. Selected Articles from This Issue.
    Clin Cancer Res; 2020 Jun; 26(11):2437. PubMed ID: 32482655
    [No Abstract]   [Full Text] [Related]  

  • 40. AIMECS 07 - Sixth AFMC International Medicinal Chemistry Symposium: recent approaches in anticancer therapy.
    Valla V
    IDrugs; 2007 Sep; 10(9):614-7. PubMed ID: 17786841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.